Menu Search
Equities

BioInvent International AB

BINVs:EBT

BioInvent International AB

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year BioInvent International AB's revenues fell -78.09% from 326.13m to 71.46m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 42.50m to a larger loss of 330.30m.
Gross margin--
Net profit margin-728.09%
Operating margin-816.96%
Return on assets-27.41%
Return on equity-29.80%
Return on investment-29.50%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at BioInvent International AB fell by 255.50m. However, Cash Flow from Investing totalled 59.68m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 338.32m for operations while cash generated from financing totalled 23.14m.
Cash flow per share-5.55
Price/Cash flow per share--
Book value per share16.68
Tangible book value per share16.68
More ▼

Balance sheet in SEKView more

BioInvent International AB has little financial risk as the capital structure does not rely on leverage.
Current ratio12.30
Quick ratio12.18
Total debt/total equity0.0174
Total debt/total capital0.0171
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.